3月11日 - ** 总部位于马里兰州的疫苗生产商NovavaxNVAX.O股价下跌2.8%至7.96美元
** 公司称，由于错过了 COVID-19 疫苗的监管审批期限，公司于 3 月 7 日收到 (link) 通知，即刻终止与加拿大的购买协议。
** 公司于 2021 年 1 月与加拿大签订了购买协议
** 根据协议条款，公司之前收到的2800万美元预付款将在通知后30天内退还给客户。
** 截至上次收盘，NVAX 在过去 12 个月中上涨了 50.
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.